Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL457945 | 0.81 | CYP3A4 (0.31) | — | |
| SCHEMBL17020424 | 0.75 | SMN1; SMN2 (0.33) | SMN1; SMN2LMNAPOLBKDM4E | |
| SCHEMBL460915 | 0.75 | SMN1; SMN2 (0.33) | SMN1; SMN2LMNAPOLBKDM4E | |
| SCHEMBL470411 | 0.74 | KDM4E (0.32) | SMN1; SMN2LMNAKDM4E | |
| SCHEMBL458947 | 0.73 | KDM4E (0.50) | SMN1; SMN2LMNAKDM4ETDP1L3MBTL1 | |
| SCHEMBL13035743 | 0.72 | ALDH1A1 (0.34) | LMNAPOLB | |
| SCHEMBL462614 | 0.71 | KDM4E (0.42) | SMN1; SMN2POLBKDM4ETDP1L3MBTL1 | |
| SCHEMBL457888 | 0.71 | MAPT (0.47) | SMN1; SMN2POLBKDM4ETHRB | |
| SCHEMBL470294 | 0.70 | ALDH1A1 (0.43) | POLBKDM4ETDP1L3MBTL1 | |
| SCHEMBL13074207 | 0.69 | KDM4E (0.39) | SMN1; SMN2LMNAKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633200-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633200-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633200-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2614064-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20120225888-A1 | Inhibitors of Human Immunodeficiency Virus Replication | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-06 | — | — | US | disclosed |
| US-20120225888-A1 | Inhibitors of Human Immunodeficiency Virus Replication | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-06 | — | — | US | disclosed |
| US-20120225888-A1 | Inhibitors of Human Immunodeficiency Virus Replication | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-06 | — | — | US | disclosed |
| WO-2012033735-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012033735-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225888-A1 | Inhibitors of Human Immunodeficiency Virus Replication | EIF2AK2, RTF2, MAVS | SMN1; SMN2 2947/4885LMNA 3885/4885POLB 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.